EMAIL THIS PAGE TO A FRIEND

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.


PMID 25017765

Abstract

Chronic graft-versus-host disease (GVHD) induces significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Corticosteroids are standard initial therapy, despite limited efficacy and long-term toxicity. Based on our experience using bortezomib as effective acute GVHD prophylaxis, we hypothesized that proteasome-inhibition would complement the immunomodulatory effects of corticosteroids to improve outcomes in chronic GVHD (cGVHD). We undertook a single-arm phase II trial of bortezomib plus prednisone for initial therapy of cGVHD. Bortezomib was administered at 1.3 mg/m(2) i.v. on days 1, 8, 15, and 22 of each 35-day cycle for 3 cycles (15 weeks). Prednisone was dosed at .5 to 1 mg/kg/day, with a suggested taper after cycle 1. All 22 enrolled participants were evaluable for toxicity; 20 were evaluable for response. Bortezomib plus prednisone therapy was well tolerated, with 1 occurrence of grade 3 sensory peripheral neuropathy possibly related to bortezomib. The overall response rate at week 15 in evaluable participants was 80%, including 2 (10%) complete and 14 (70%) partial responses. The organ-specific complete response rate was 73% for skin, 53% for liver, 75% for gastrointestinal tract, and 33% for joint, muscle, or fascia involvement. The median prednisone dose decreased from 50 mg/day to 20 mg/day at week 15 (P < .001). The combination of bortezomib and prednisone for initial treatment of cGVHD is feasible and well tolerated. We observed a high response rate to combined bortezomib and prednisone therapy; however, in this single-arm study, we could not directly measure the impact of bortezomib. Proteasome inhibition may offer benefit in the treatment of cGVHD and should be further evaluated.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA004252
Anti-CD4 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA004472
Anti-CD4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1405577
Anti-CD8A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA037756
Anti-CD8A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4700110
Monoclonal Anti-CD19-APC antibody produced in mouse, clone LT19, purified immunoglobulin, buffered aqueous solution
SAB4700717 Monoclonal Anti-CD19-APC antibody produced in mouse, clone 4G7, purified immunoglobulin, buffered aqueous solution
SAB4700059
Monoclonal Anti-CD4 , (N-terminal) antibody produced in mouse, clone MEM-241, purified immunoglobulin, buffered aqueous solution
C1805 Monoclonal Anti-CD4 antibody produced in mouse, clone Q4120, purified immunoglobulin, buffered aqueous solution
SAB4700054 Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-16, purified immunoglobulin, buffered aqueous solution
SAB4700065
Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-115, purified immunoglobulin, buffered aqueous solution
SAB4700733 Monoclonal Anti-CD4 antibody produced in mouse, clone OX-35, purified immunoglobulin, buffered aqueous solution
SAB4100489
Monoclonal Anti-CD4 antibody produced in mouse, clone CD4 -A409, culture supernatant
AMAB90754
Monoclonal Anti-CD4 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0395, purified immunoglobulin, buffered aqueous glycerol solution
SAB4700453
Monoclonal Anti-CD56-PE antibody produced in mouse, clone MEM-188, purified immunoglobulin, buffered aqueous solution
C7423
Monoclonal Anti-CD8 antibody produced in mouse, clone UCHT-4, purified immunoglobulin, buffered aqueous solution
SAB4700084 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-31, purified immunoglobulin, buffered aqueous solution
SAB4700089 Monoclonal Anti-CD8 antibody produced in mouse, clone MEM-87, purified immunoglobulin, buffered aqueous solution
SAB1402142
Monoclonal Anti-CD8A antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution